CorA human medicine
- Summary
- Corallopyronin A is a new antibiotic in filarial and dirofilarial infections with a new mode of action resulting in fewer adverse reaction and unlikelyness of resistances development.
- Technology Benefits
- Effective control of dirofilarial infections
Kills larvae as well as adult worms
Requires fewer treatment cycles in logistically difficult regions
Treatment of children is probable
Oral administration is possible
Alternative mode of action avoids selection for rifampicin cross-resistant M. tuberculosis
- Technology Application
- The current treatment approach targets the worm itself. The drugs, e.g. diethylcarbamazine and ivermectin, mainly kill larvae.
- Detailed Technology Description
- Corallopyronin A (CorA) has efficacy against the intracellular Wolbachia of filarial nematodes. Experiments in mice show that all worms were depleted of more than 98% of their Wolbachia, resulting in blocked larval development and phenotypically altered worms. The results indicate the potential of CorA to effectively eliminate filarial disease by killing larvae as well as adult worms with one (maximum of two) treatment regimens.
- Type of Cooperation
- Licensing
- Application Date
- 04/05/2012 00:00:00
- Application No.
- EP20120721456 20120504
- Classes
- - international:
A61K31/366; A61P31/04; A61P33/00
- cooperative:
A61K31/366; C07D309/38; Y02A50/421; Y02A50/422
- Others
- Patent application
- ID No.
- 2838
- Country/Region
- Germany
For more information, please click Here
